High facility preference for rivaroxaban in atrial fibrillation increases risk of major bleeding compared to facility preference for apixaban

Back

ESC Premium Access

High facility preference for rivaroxaban in atrial fibrillation increases risk of major bleeding compared to facility preference for apixaban

Session: Poster Session 5 - Atrial fibrillation and oral anticoagulation 4

Topic: Stroke Prevention

Speaker: Doctor A. Nissen Bonde (Gentofte, DK)

Event: ESC Congress 2019

Congress Presentation

About the speaker

Doctor Anders Nissen Bonde

Gentofte University Hospital, Gentofte (Denmark)

0 follower

8 more presentations in this session

Oral anticoagulants in patients with atrial fibrillation having an intermediate risk of ischemic stroke but a high risk of bleeding

Speaker: Doctor T. Chao (Taipei, TW)

Access

Abstract

Older patients with atrial fibrillation and comorbidities are less likely to be treated with oral anticoagulation: insights from a nationwide study

Speaker: Doctor P. Rasmussen (Copenhagen, DK)

Access

Abstract

Slides

Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation in real-world clinical practice: the SPECTRUM post-approval safety study

Speaker: Professor J. Hartikainen (Kuopio, FI)

Access

Abstract

Slides

Age-dependent anti-thrombotic therapy for atrial fibrillation patients with intermediate risk (CHA2DS2-VASc Score of 1 or 2) of ischemic stroke

Speaker: Associate Professor S. Choi (Daegu, KR)

Access

Abstract

Slides

Mortality in patients with non-valvular atrial fibrillation in South America. Warfarin has significant higher global mortality rates versus dabigatran and rivaroxaban

Speaker: Doctor G. Vanerio (Montevideo, UY)

Access

Abstract

Access the full session

Poster Session 5 - Atrial fibrillation and oral anticoagulation 4

Speakers: Doctor A. Nissen Bonde, Doctor T. Chao, Doctor P. Rasmussen, Professor J. Hartikainen, Associate Professor S. Choi...

Access

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

High facility preference for rivaroxaban in atrial fibrillation increases risk of major bleeding compared to facility preference for apixaban

About the speaker

Doctor Anders Nissen Bonde

8 more presentations in this session

Oral anticoagulants in patients with atrial fibrillation having an intermediate risk of ischemic stroke but a high risk of bleeding

Older patients with atrial fibrillation and comorbidities are less likely to be treated with oral anticoagulation: insights from a nationwide study

Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation in real-world clinical practice: the SPECTRUM post-approval safety study

Age-dependent anti-thrombotic therapy for atrial fibrillation patients with intermediate risk (CHA2DS2-VASc Score of 1 or 2) of ischemic stroke

Mortality in patients with non-valvular atrial fibrillation in South America. Warfarin has significant higher global mortality rates versus dabigatran and rivaroxaban

Access the full session

Poster Session 5 - Atrial fibrillation and oral anticoagulation 4

About the event

ESC Congress 2019

ESC 365 is supported by